PVH Corp Jumped On Earnings – PVH, MCP, RPRX, ANGI
PVH Corp (NYSE:PVH) stock gained 5.38% to $93.25 in the after hour trading after Citigroup reconfirmed their buy rating on shares of Phillips-Van Heusen (NYSE: PVH) in a report issued yesterday and they currently have a $104.00 target price on the stock.
Additionally, the company reported second quarter net income of $87.7 million or $1.19 per share, as compared to $66.7 million or $0.92 per share for the year-ago quarter. Adjusted net income for the second quarter was $92.0 million or $1.25 per share. Total revenue grew to $1.34 billion from $1.33 billion in the same quarter last year. Analysts expected the company to earn $1.20 per share on revenue estimate of $1.34 billion for the second quarter.
Looking further, the company expects third quarter of 2012 revenue to decrease 2% to 3% as compared to the third quarter of 2011 amount of $1.654 billion and on a non-GAAP basis, earnings per share (EPS) is currently projected to be in the range of $2.20 to $2.25. Analysts were expecting the Company to report revenue of $1.664 billion and EPS of $2.20 for the third quarter of 2012.
Molycorp, Inc. (NYSE:MCP) shares climbed 5.88% to $10.08 in the after hour trading after the company announced the start-up of its new Project Phoenix heavy rare earth concentrate facilities at Mountain Pass, California, which will produce heavy rare earth concentrate from freshly mined Mountain Pass ore that will then be processed into high-purity, custom-engineered heavy rare earth products in Molycorp’s globally integrated production facilities.
Repros Therapeutics Inc. (NASDAQ:RPRX) announced yesterday that the U.S. Food and Drug Administration or FDA has provided guidance for a Phase 2 study of low dose oral Proellex in the treatment of endometriosis.
The company also said it plans to submit the revised protocol to the FDA as soon as practicable. Once received, the FDA agreed to review the design within 30 days, at which time, if the protocol is acceptable, Repros could commence the Phase 2 trial in the fourth quarter of this year.
Angie’s List Inc (NASDAQ:ANGI) shares are being covered by Barrington Research in a research note released yesterday and the firm issued a market perform rating on the stock. The company last released its earnings data on July 25. The company reported ($0.41) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.39) by $0.02. Angie’s List’s revenue was up 74.2% compared to the same quarter last year. Analysts expect that Angie’s List will post $-1.04 EPS for the current fiscal year.